REEV, a pioneering medical technology startup developing intelligent, lightweight wearable robotics, announced a $9.2 million funding round to accelerate its mission of transforming mobility assistance for patients with movement disorders.
The funding round was led by Newfund Heka, Polytechnique Ventures and Irdi Capital, with additional support from Techstars and a group of business angels and health care operators. Contributors include French soccer player Raphael Varane and knee surgeon Herve Silbert, assembled by Scala Patrimoine, a multi-family office.
Related: Neuromod developer NeuroPace announces $65m offering
The company’s technology portfolio includes two key solutions:
— REEV SENSE, a motion sensor system that attaches to a patient’s shoe or leg, delivering precise gait analysis.
— DREEVEN, a wearable robotics system using electro-hydraulic technology to provide personalized knee assistance.
The company aims to address limitations in existing exoskeleton technologies by reducing device weight, lowering costs and enhancing personalization. The first DREEVEN series is expected to launch in 2026.
Recent achievements include:
— A clinical study at MIT’s Center for Clinical and Translational Research, funded through a grant from the Massachusetts Technology Collaborative’s Massachusetts eHealth Institute (MeHI)
— Production of 100 REEV SENSE commercial units with FDA and CE medical certifications.
— Initial testing of DREEVEN functional units with patients.
The funding will support finalizing DREEVEN’s design, conducting a clinical study at the Neuromotor Recovery Lab at Boston University’s Sargent College of Health & Rehabilitation Sciences under the leadership of Dr. Lou Awad, and preparing for U.S. Food and Drug Administration trials.
“With the support of our world-class partners, we are thrilled to enter the next phase of clinical and industrial development,” said Amaury Ciurana, Co-Founder and CEO of REEV. “Our innovative technologies, like the DREEVEN motorized orthosis, aim to redefine mobility assistance, transforming lives and reshaping the orthotics industry.”
“We are proud to continue supporting REEV as they work toward FDA clearance to bring their technology to market in the U.S. This marks a key milestone in improving mobility for neurological patients,” said Anne-Sophie Saint-Martin, Partner at Newfund.
